Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $18.1 million.

  • Amicus Therapeutics' Share-based Compensation fell 320.53% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.0 million, marking a year-over-year decrease of 447.11%. This contributed to the annual value of $84.9 million for FY2024, which is 136.16% down from last year.
  • According to the latest figures from Q3 2025, Amicus Therapeutics' Share-based Compensation is $18.1 million, which was down 320.53% from $17.6 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Share-based Compensation registered a high of $34.9 million during Q1 2023, and its lowest value of $11.7 million during Q2 2021.
  • Its 5-year average for Share-based Compensation is $19.3 million, with a median of $18.1 million in 2025.
  • Within the past 5 years, the most significant YoY rise in Amicus Therapeutics' Share-based Compensation was 6159.1% (2021), while the steepest drop was 2556.58% (2021).
  • Amicus Therapeutics' Share-based Compensation (Quarter) stood at $13.9 million in 2021, then surged by 33.93% to $18.6 million in 2022, then dropped by 2.85% to $18.1 million in 2023, then rose by 6.2% to $19.2 million in 2024, then decreased by 5.87% to $18.1 million in 2025.
  • Its Share-based Compensation stands at $18.1 million for Q3 2025, versus $17.6 million for Q2 2025 and $25.2 million for Q1 2025.